Company Overview and News
KUALA LUMPUR (April 12): The FBM KLCI retreated at mid-morning today, in line with the jittery regional markets.
KUALA LUMPUR (April 11): The FBM KLCI remained in the negative zone amid some choppy trade this morning, in line with the regional markets that came under pressure as geopolitical risks mounted.
KUALA LUMPUR (April 11): The FBM KLCI continued to remain under pressure in early trade this morning, in line with most regional markets.
KUALA LUMPUR (April 6): The FBM KLCI fell 0.28% and slipped to below the 1,740-point level at the midday break today, in line with the lacklustre regional markets.
KUALA LUMPUR (April 6): The FBM KLCI extended its losses at mid-morning today, in line with the lacklustre regional markets.
KUALA LUMPUR (April 6): The FBM KLCI dipped in early trade this morning in line with the weaker start at most regional markets.
TENAGA Nasional Bhd (TNB) through its subsidiary TNB Remaco, has signed a memorandum of understanding (MoU) with Indian-based GMR Energy Ltd to collaborate in a power plant operations and maintenance venture in India.
KUALA LUMPUR: Fund buying of Genting Malaysia and banks underpinned the FBM KLCI's gains at midday on Monday while Asian markets were mostly higher except Japan and South Korea. At 12.30pm, the KLCI was up 10.96 points or 0.64% to 1,719.34 after falling more than seven points last Friday. Turnover was robust with 1.72 billion shares traded valued at RM1.07bil. There were 443 gainers, 350 losers and 352 counters unchanged.
KUALA LUMPUR (March 6): The FBM KLCI rose 0.64% at the midday break today, lifted by gains including at index-linked blue chips.
KUALA LUMPUR (March 6): The FBM KLCI remained above the 1,710-point level at mid-morning today, lifted by select blue chips.
KUALA LUMPUR (Feb 27): The FBM KLCI struggled to to remain above the 1,700-point level at the midday break today as sellling persisted on Bursa Malaysia, despite the regional markets reversing earlier losses.
KUALA LUMPUR (Feb 27): The FBM KLCI clawed back to above the 1,700-point level at mid-morning today,lifted by select blue chips.
KUALA LUMPUR (Jan 31): The FBM KLCI fell 0.58% at the midday break today as renewed concerns over US President Donald Trump's policy decisions kept investors on tenterhooks.
7h - Asif
Overview Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on advancing the development and commercialization of innovative medicines that benefit patients with unmet medical needs. The company currently have two compounds in development, Sollpura and blisibimod. The company licensed Sollpura from Eli Lilly & Co (“Eli Lilly”) in July 2014. Sollpura is a novel non-porcine investigational Pancreatic Enzyme Replacement Therapy (“PERT”) intended for the treatment of patients with Exocrine Pancreatic Insufficiency (“EPI”), often seen in patients with cystic fibrosis and other conditions. The company licensed blisibimod from Amgen, Inc. (“Amgen”) in December 2007. Blisibimod targets B-cell activating factor, or BAFF, which has been shown to be elevated in a variety of B-cell mediated autoimmune diseases, including Immunoglobulin A nephropathy, or IgA nephropathy. Sollpura The exocrine pancreas is responsible for synthesis and secretion of digestive en...
8h - Asif
Business Agenus is a clinical-stage immuno-oncology (“I-O”) company dedicated to becoming a leader in the discovery and development of innovative combination therapies and committed to bringing effective medicines to patients with cancer. The company's business is designed to drive success in I-O through speed, innovation, and effective combination therapies. Agenus has assembled fully integrated capabilities from novel target discovery, antibody generation, cell line development, and good manufacturing practice (“GMP”) manufacturing together with a comprehensive portfolio consisting of antibody-based therapeutics, adjuvants and cancer vaccine platforms. The company leverage its immune biology platforms to identify effective combination therapies for development and have developed productive partnerships to advance its innovation. The company believe the next generation of cancer treatment will build on clinically validated antibodies targeting CTLA-4 and PD-1 combined wi...
18h - Asif
Business The company started Square in February 2009 to enable businesses (sellers) to accept card payments, an important capability that was previously inaccessible to many businesses. However, sellers also need innovative solutions to thrive, and Square has since expanded to provide additional products and services to give these businesses access to the same tools as large businesses. This approach aligns with its purpose of economic empowerment, as everything the company do should give sellers accessible, affordable tools to grow their businesses and participate in the economy. Square is a cohesive commerce ecosystem that helps its sellers start, run, and grow their businesses. The company combine sophisticated software with affordable hardware to enable sellers to turn mobile and computing devices into powerful payment and point-of-sale solutions. Square has high seller acceptance rates and fast onboarding, while maintaining low risk and fraud losses as a result of its a...